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Does azithromycin have a role  
in cesarean sections? 
Yes, adding azithromycin to the usual antibiotic protocol 
in nonelective c-sections reduces infections. But not 
everyone can take advantage of it. 
PRACTICE CHANGER
Prescribe a one-time dose of azithromycin 
500 mg intravenously, along with standard 
antibiotic prophylaxis, at the time of cesarean 
delivery to prevent postoperative infections.1
STRENGTH OF RECOMMENDATION
B: Based on a single good-quality, random-
ized controlled trial.
Tita AT, Szychowski JM, Boggess K, et al. Adjunctive azithromycin pro-
phylaxis for cesarean delivery. N Engl J Med. 2016;375:1231-1241.
ILLUSTRATIVE CASE
A 26-year-old G1P0 at 40w1d presents in spon-
taneous labor and is dilated to 4 cm. The pa-
tient reached complete cervical dilation after 
artificial rupture of membranes and oxytocin 
augmentation. After 4 hours of pushing, there 
has been minimal descent of the fetal vertex 
beyond +1 station with significant caput suc-
cedaneum. Her physician decides to proceed 
with cesarean delivery.2,3 What antibiotics 
should be administered prior to incision to re-
duce postoperative infection? 
The Centers for Disease Control and Prevention (CDC) reports that nearly 1.3 million cesarean deliveries were 
performed in the United States in 2015, 
which represents about a third of all births.4 
C-section is the most common major sur-
gical procedure performed in this country 
and is associated with an infection rate 5 to 
10 times that of vaginal delivery.5,6 Pregnancy- 
associated infection, particularly during 
delivery, is a significant risk and the fourth 
most common cause of maternal death in the 
United States.5 
The current standard of care in cesar-
ean delivery is antibiotic prophylaxis (often 
a first-generation cephalosporin) prior to 
skin incision.7 The majority of c-sections per-
formed are nonelective, and of these, post-
operative infections occur in 12% of women 
who receive standard prophylaxis.8,9 A small, 
single-center design trial suggested azithro-
mycin adjunctive therapy expands antibiotic 
coverage to Ureaplasma species, resulting in 
a lower risk of postoperative infection.10 
This study evaluated the use of azithro-
mycin adjunctive therapy, in addition to stan-
dard antibiotic prophylaxis, to reduce the risk 
of postoperative infections in women receiv-
ing nonelective c-sections.
STUDY SUMMARY
Azithromycin reduced maternal  
infections up to 6 weeks post–c-section
A multicenter, randomized double-blind trial 
conducted in 14 hospitals in the United States 
evaluated the effect of a one-time dose of 
500 mg intravenous (IV) azithromycin on post-
cesarean infections. Women with a singleton 
pregnancy of at least 24 weeks’ gestation were 
eligible for inclusion if they required nonelec-
tive cesarean delivery during labor or at least 
4 hours after membrane rupture. Patients were 
excluded if they had a known azithromycin 
allergy, subsequent vaginal delivery, azithro-
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mycin use within the week prior to random-
ization, extensive hepatic or renal dysfunction, 
a known history of prolonged QT interval, or 
substantial electrolyte abnormalities. Patients 
were eligible even if they were receiving other 
antibiotics for a positive group B Streptococcus 
screening.1
All patients (N=2013) were treated with 
standard antibiotic prophylaxis, most often 
cefazolin, according to individual institution 
protocols. The women were randomized to re-
ceive either an azithromycin 500 mg/250 mL 
IV infusion (n=1019) or an identical placebo 
IV infusion (n=994) within one hour of the 
procedure. The primary outcome was a com-
posite endpoint of endometritis, wound in-
fection, or other infections occurring up to 
6 weeks after the c-section. Secondary out-
comes included neonatal death, sepsis, and 
other neonatal and maternal complications.1
Patients in the placebo group had a 
higher rate of smoking during pregnancy; 
the researchers found no other significant 
differences.1
❚ Results. The primary composite out-
come occurred less frequently in the azithro-
mycin group than in the placebo group (6.1% 
vs 12.1%; relative risk [RR]=0.51; 95% confi-
dence interval [CI], 0.38-0.68; number needed 
to treat [NNT]=17). When the researchers 
looked at the individual elements of the pri-
mary composite outcome, 2 had significant 
reductions vs placebo. 
Endometritis (3.8% vs 6.1%; RR=0.62; 
95% CI, 0.42-0.92; NNT=44) and wound in-
fections (2.4% vs 6.6%; RR=0.35; 95% CI, 0.22-
0.56; NNT=24) occurred significantly less 
frequently, but there was no difference for 
other infections (0.3% vs 0.6%; RR=0.49; 95% 
CI, 0.12-1.94). Serious maternal adverse events 
were also lower with treatment than in the 
control group (1.5% vs 2.9%; RR=0.5; 95% CI, 
0.27-0.94; NNT=71). There was no difference 
in composite secondary neonatal outcomes 
including death and serious complications 
(14.3% vs 13.6%; RR=1.05; 95% CI, 0.85-1.31).1
WHAT’S NEW
Azithromycin reduces infections  
without increasing adverse events
This study showed that adding azithromycin 
to standard antibiotic prophylaxis within one 
hour of a c-section reduces post-cesarean 
delivery infection rates without increasing 
the risk of maternal or neonatal adverse 
events.
CAVEATS
Proceed with caution in those  
with prolonged QT intervals
While azithromycin was efficacious and well 
tolerated in the study, not every patient can 
take it. Patients with a previous drug reaction 
or allergy should avoid it, and experts advise 
prescribing it with caution for patients who 
have (or are at increased risk for) a prolonged 
QT interval, including those on other QT- 
prolonging medications.
Of note, women with scheduled 
c-sections and those with chorioamnionitis 
or another infection requiring postpartum 
antibiotics were excluded from this study. 
Thus, it is unknown if azithromycin use de-
creases complications in these patients.
CHALLENGES TO IMPLEMENTATION
Speed of procedure is often paramount, 
so drug availability is key
Nonelective c-sections occur based on many 
factors that include a non-reassuring fetal 
heart rate. In many of these cases, speed of 
cesarean delivery may mean the difference 
between positive and negative outcomes. 
Availability of azithromycin on labor and de-
livery floors for timely administration within 
one hour of the procedure is important. 
Additionally, azithromycin has known 
QT prolongation risks.11 While the baseline 
QT interval is not known for many healthy, 
young women, this should be considered 
when azithromycin is utilized in combination 
with other medications that may prolong the 
QT interval.                 JFP
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